Stockscreener 앱 받기
0.29%
시간 외 거래:
Amgen Inc 주식(AMGN)의 최신 뉴스
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Benzinga
Amgen Defends Tavneos Amid FDA Withdrawal Proposal - GuruFocus
Cash from investing activities of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Amgen taps research firm to reassess Tavneos data - TradingView
Piper Sandler reiterates Amgen stock rating on Sjogren’s drug By Investing.com - Investing.com Canada
Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight - GuruFocus
(AMGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $427 - Moomoo
Amgen Inc. $AMGN Position Reduced by Vaughan David Investments LLC IL - MarketBeat
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend. - The Motley Fool
Nuveen LLC Sells 86,287 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Stock (US0311621009): Shares Jump On EU Cancer Drug Approval And New Trial Data - AD HOC NEWS
Amgen Inc. Stock (US0311621009): Dow component under pressure after recent pullback - AD HOC NEWS
Amgen (AMGN) Faces FDA Scrutiny Over Tavneos Amid Safety Concerns - GuruFocus
A Look at Amgen Inc (AMGN) After 4.8% Gain -- GF Value $353.35 vs Price $354.06 - GuruFocus
Amgen hires Duke research organization to save Tavneos from market removal - Seeking Alpha
Amgen taps Duke Research Institute to reevaluate disputed Tavneos data - Investing.com
Amgen taps Duke Research Institute to reevaluate disputed Tavneos data By Investing.com - Investing.com Canada
Amgen’s Repatha Diabetes Data Reframes Cardiometabolic Upside For Investors - simplywall.st
Amgen Reevaluates Tavneos Data as Medicine Faces FDA Scrutiny - Bloomberg.com
Amgen Hires Avenue Solutions for Medicare Lobbying - Legis1
Amgen Named Among World’s Most Impactful Companies 2026 by TIME - Amgen
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now - Insider Monkey
Dow's 750-Point Rally Led By Gains In Shares Of Amgen, Boeing - Moomoo
Amgen, Honeywell Share Gains Lead Dow's 265-Point Jump - Moomoo
Caterpillar, Amgen Share Gains Lead Dow's 414-Point Jump - 富途牛牛
Is Amgen Inc. (AMGN) A Good Stock To Buy Now? - Insider Monkey
Amgen Inc Stock (AMGN) Moved Up by 3.35% on Jun 11: What Signal Does It Send? - TradingKey
Dow Rallies 288 Points On Gains For Amgen, Caterpillar Shares - 富途牛牛
Renaissance Group LLC Has $36.95 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
J.Safra Asset Management Corp Takes Position in Amgen Inc. $AMGN - MarketBeat
Townsquare Capital LLC Sells 3,602 Shares of Amgen Inc. $AMGN - MarketBeat
Janney Montgomery Scott LLC Has $141.09 Million Stake in Amgen Inc. $AMGN - MarketBeat
ING Groep NV Buys New Shares in Amgen Inc. $AMGN - MarketBeat
Gilpin Wealth Management LLC Takes Position in Amgen Inc. $AMGN - MarketBeat
Capital Wealth Planning LLC Raises Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Amgen Can't Amend Petition To Address Potential Double Tax - Law360
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
AMGN Maintains by Morgan Stanley -- Price Target Raised to $340 - GuruFocus
What Amgen CFO Told Goldman Sachs About the IRS, MariTide, and Why the Stock May Be Worth $467 - TIKR.com
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market? - Yahoo Finance
Motley Fool Asset Management LLC Increases Position in Amgen Inc. $AMGN - MarketBeat
Amgen eyes 2026 'springboard' as growth drugs offset patent pressure - MSN
Morgan Stanley raises Amgen stock price target on obesity drug potential - Investing.com Canada
Amgen Inc. stock (US0311621009): focus on weight-loss and cancer pipeline after latest earnings - AD HOC NEWS
Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure - MarketBeat
Amgen Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Is It Too Late To Consider Amgen (AMGN) After Its Strong Multi Year Share Price Run? - Yahoo Finance
Amgen Inc. $AMGN Shares Purchased by LPL Financial LLC - MarketBeat
Franklin Resources Inc. Has $712.09 Million Stake in Amgen Inc. $AMGN - MarketBeat
Cerity Partners LLC Has $134.82 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
AMGN|Amgen Inc|Price:349.076|Chg%:11.35 - TradingKey
Goldman Sachs Trims Amgen (AMGN) Valuation but Sticks with Buy Rating - Yahoo Finance
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Amgen stock (US0311621009): FDA filing and pipeline momentum in focus - AD HOC NEWS
Why Amgen Inc (AMGN) Is Set to Outperform the Market: Insights i - GuruFocus
AMGN DCF Analysis: Intrinsic Value $292 vs Price $350 - GuruFocus
Can MariTide Save Amgen Stock From Its Fading Blockbusters? - Trefis
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
O Shaughnessy Asset Management LLC Buys 27,035 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. stock (US0311621009): Weight-loss pipeline and Horizon deal keep biotech in focus - AD HOC NEWS
Hilton Head Capital Partners LLC Purchases Shares of 3,798 Amgen Inc. $AMGN - MarketBeat
Los Angeles Capital Management LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Erste Asset Management GmbH - MarketBeat
Brandywine Global Investment Management LLC Has $140 Million Holdings in Amgen Inc. $AMGN - MarketBeat
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS - Amgen
Amgen (AMGN) Unveils Promising Data on Diabetes at ADA Conferenc - GuruFocus
What to know about MariTide, Amgen’s experimental GLP-1 drug - AOL.com
0.33%
0.22%
자본화:
|
볼륨(24시간):